Assignee
BEIGENE LTD
KY·58 granted patents·66 pending applications·996 citations·filing 2013–2025
Top patents by PatentIndex Score
124 records- 0198US9834606B2Anti-PD1 antibodies and their use as therapeutics and diagnosticsBEIGENE LTD·Filed 2015·Granted Dec 5, 2017·66 cites·11 claims
- 0298US9217034B2Anti-PD1 antibodies and their use as therapeutics and diagnosticsBEIGENE LTD·Filed 2014·Granted Dec 22, 2015·55 cites·32 claims
- 0398US8735553B1Anti-PD1 antibodies and their use as therapeutics and diagnosticsBEIGENE LTD·Filed 2013·Granted May 27, 2014·583 cites·35 claims
- 0497US10570139B2Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulatorsBEIGENE LTD·Filed 2018·Granted Feb 25, 2020·24 cites·15 claims
- 0597US10519235B2Anti-PD1 antibodies and their use as therapeutics and diagnosticsBEIGENE LTD·Filed 2018·Granted Dec 31, 2019·16 cites·10 claims
- 0697US10005782B2Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulatorsBEIGENE LTD·Filed 2016·Granted Jun 26, 2018·23 cites·21 claims
- 0797US9556188B2Substituted imidazo[1,2-b]pyrazoles as bruton'S tyrosine kinase modulatorsBEIGENE LTD·Filed 2015·Granted Jan 31, 2017·24 cites·15 claims
- 0897US9447106B2Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulatorsBEIGENE LTD·Filed 2015·Granted Sep 20, 2016·30 cites·23 claims
- 0996US9988450B2Anti-PD1 antibodies and their use as therapeutics and diagnosticsBEIGENE LTD·Filed 2017·Granted Jun 5, 2018·22 cites·22 claims
- 1093US11512132B2Anti-PD-L1 antibodies and their use as therapeutics and diagnosticsBEIGENE LTD·Filed 2019·Granted Nov 29, 2022·10 cites·14 claims
- 1193US11203637B2Anti-Tim-3 antibodies and use thereofBEIGENE LTD·Filed 2017·Granted Dec 21, 2021·8 cites·29 claims
- 1293US10864203B2Combination of a PD-1 antagonist and a RAF inhibitor for treating cancerBEIGENE LTD·Filed 2017·Granted Dec 15, 2020·10 cites·13 claims
- 1393US10544225B2Anti-PD-L1 antibodies and their use as therapeutics and diagnosticsBEIGENE LTD·Filed 2015·Granted Jan 28, 2020·15 cites·12 claims
- 1492US12077536B2BCL-2 inhibitorsBEIGENE LTD·Filed 2022·Granted Sep 3, 2024·4 cites·23 claims
- 1592US11202782B2Treatment cancers using a combination comprising PARP inhibitorsBEIGENE LTD·Filed 2017·Granted Dec 21, 2021·9 cites·29 claims
- 1692US10112952B2Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitorsBEIGENE LTD·Filed 2017·Granted Oct 30, 2018·5 cites·17 claims
- 1790US9393232B2Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-onesBEIGENE LTD·Filed 2014·Granted Jul 19, 2016·15 cites·12 claims
- 1889US11420968B2Bcl-2 inhibitorsBEIGENE LTD·Filed 2019·Granted Aug 23, 2022·7 cites·39 claims
- 1987US11597768B2Immunotherapy for hepatocellular carcinomaBEIGENE LTD·Filed 2018·Granted Mar 7, 2023·7 cites·13 claims
- 2087US10501467B2Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitorsBEIGENE LTD·Filed 2018·Granted Dec 10, 2019·2 cites·17 claims
- 2187US9617273B2Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitorsBEIGENE LTD·Filed 2016·Granted Apr 11, 2017·6 cites·10 claims
- 2286US11393566B1Interoperable platform for reducing redundancy in medical database managementBEIGENE LTD·Filed 2021·Granted Jul 19, 2022·2 cites·20 claims
- 2386US10351559B2Maleate salts of a B-RAF kinase inhibitor, crystalline forms, methods of preparation, and uses thereforeBEIGENE LTD·Filed 2016·Granted Jul 16, 2019·2 cites·46 claims
- 2485US11555038B2Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereofBEIGENE LTD·Filed 2018·Granted Jan 17, 2023·7 cites·7 claims
- 2585US11220506B2Imidazo[1,5-a]pyrazine derivatives as PI3Kdelta inhibitorsBEIGENE LTD·Filed 2018·Granted Jan 11, 2022·2 cites·22 claims
- 2685US10280163B25 or 8-substituted imidazo[1, 5-a] pyridines as indoleamine and/or tryptophane 2, 3-dioxygenasesBEIGENE LTD·Filed 2016·Granted May 7, 2019·5 cites·30 claims
- 2784US11534431B2Combination of a PD-1 antagonist and a RAF inhibitor for treating cancerBEIGENE LTD·Filed 2020·Granted Dec 27, 2022·1 cites·21 claims
- 2884US11377449B2BTK inhibitors with improved dual selectivityBEIGENE LTD·Filed 2018·Granted Jul 5, 2022·3 cites·22 claims
- 2983US12195449B23-[(1H-pyrazol-r-yl)oxy]pyrazin-2-amine compounds as HPK1 inhibitor and use thereofBEIGENE LTD·Filed 2024·Granted Jan 14, 2025·0 cites·17 claims
- 3083US11136323B2Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitorsBEIGENE LTD·Filed 2017·Granted Oct 5, 2021·2 cites·34 claims
- 3183US9920055B2Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitorsBEIGENE LTD·Filed 2017·Granted Mar 20, 2018·3 cites·20 claims
- 3282US9895376B2Fused tricyclic compounds as Raf kinase inhibitorsBEIGENE LTD·Filed 2016·Granted Feb 20, 2018·3 cites·17 claims
- 3382US9670203B2Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitorsBEIGENE LTD·Filed 2014·Granted Jun 6, 2017·4 cites·24 claims
- 3481US10208038B2Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitorsBEIGENE LTD·Filed 2018·Granted Feb 19, 2019·2 cites·27 claims
- 3581US2024150361A1IMIDAZO[1,5-A]PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORSBEIGENE LTD·Filed 2024·Application pending·0 cites
- 3680US10457680B2Process for preparing a PARP inhibitor, crystalline forms, and uses thereofBEIGENE LTD·Filed 2016·Granted Oct 29, 2019·3 cites·23 claims
- 3779US10899763B2Crystalline forms of salts of fused penta-cyclic dihydrodiazepinocarbazolones, and uses thereofBEIGENE LTD·Filed 2018·Granted Jan 26, 2021·1 cites·26 claims
- 3879US10647714B25 or 8-substituted imidazo[1,5-a]pyridines as indoleamine and/or tryptophane 2,3-dioxygenasesBEIGENE LTD·Filed 2019·Granted May 12, 2020·2 cites·29 claims
- 3979US10576087B2Fused tricyclic compounds as Raf kinase inhibitorsBEIGENE LTD·Filed 2018·Granted Mar 3, 2020·2 cites·16 claims
- 4078US2024376097A1BCL-2 InhibitorBEIGENE LTD·Filed 2024·Application pending·0 cites
- 4177US11472788B2Benzoimidazoles as selective inhibitors of indoleamine 2,3-dioxygenasesBEIGENE LTD·Filed 2018·Granted Oct 18, 2022·1 cites·7 claims
- 4277US11214616B2Anti-TIGIT antibodies and their use as therapeutics and diagnosticsBEIGENE LTD·Filed 2018·Granted Jan 4, 2022·1 cites·11 claims
- 4377US10562899B2Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitorsBEIGENE LTD·Filed 2019·Granted Feb 18, 2020·1 cites·27 claims
- 4477US2024376104A1Bcl-2 InhibitorsBEIGENE LTD·Filed 2024·Application pending·0 cites
- 4575US9670231B2Fused tricyclic amide compounds as multiple kinase inhibitorsBEIGENE LTD·Filed 2014·Granted Jun 6, 2017·6 cites·37 claims
- 4675US2024096462A1Interoperable platform for reducing redundancy in medical database managementBEIGENE LTD·Filed 2023·Application pending·0 cites
- 4774US12103974B2Anti-OX40 antibodies and methods of useBEIGENE LTD·Filed 2019·Granted Oct 1, 2024·1 cites·17 claims
- 4874US11875885B2Interoperable platform for reducing redundancy in medical database managementBEIGENE LTD·Filed 2023·Granted Jan 16, 2024·0 cites·20 claims
- 4973US11905294B2Imidazo[1,5-a]pyrazine derivatives as PI3Kδ inhibitorsBEIGENE LTD·Filed 2021·Granted Feb 20, 2024·0 cites·23 claims
- 5073US10882856B25 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenasesBEIGENE LTD·Filed 2017·Granted Jan 5, 2021·1 cites·33 claims
Showing the top 50 of 124 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →